# M&A Acquisitions Report - 2025-12-29

Generated on: 2025-12-29 13:37:52
Total Acquisitions: 4

## Ooma Completes Acquisition of Phone.com

**Date:** 2025-12-29
**Link:** [Ooma Completes Acquisition of Phone.com](http://www.businesswire.com/news/home/20251229179637/en/Ooma-Completes-Acquisition-of-Phone.com/)

**Summary:** SUNNYVALE, Calif.--(BUSINESS WIRE)--Ooma, Inc., a smart communications platform for businesses and consumers, today announced the successful closing of its previously announced acquisition ofPhone.com, a provider of cloud-based business communications for small and medium-sized organizations, for approximately $23.2 million in cash, subject to customary working capital adjustments. Phone.com is expected to generate $22-$23 million in revenue and $1.0-$1.5 million in adjusted EBITDA annually, based on current run rates and before synergies, and be accretive to Ooma’s Adjusted EBITDA and non-GAAP earnings per share starting on December 26, 2025. Headquartered in Newark, New Jersey, Phone.com is a cloud communications/UCaaS provider focused on serving small and medium sized businesses. LikeOo

**Contact Information:**
Director of IR and Corporate Development
Ooma, Inc.
email:
ir@ooma.com
phone: (650) 300-1480

Senior Vice President, Marketing
Ooma, Inc.
email:
press@ooma.com


---

## Johnson &amp; Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

**Date:** 2025-12-29
**Link:** [Johnson &amp; Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies](http://www.businesswire.com/news/home/20251229435345/en/Johnson-Johnson-completes-acquisition-of-Halda-Therapeutics-and-its-novel-platform-to-revolutionize-cancer-treatment-and-enable-next-generation-oral-therapies/)

**Summary:** NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. (“Halda”), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. “This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson. “We are excited to formally welcome the talented Halda team to Johnson & Johnson and look forward to working tog

**Contact Information:**
Media contact:
J&J Global Media Relations
Media-relations@its.jnj.com
Investor contact:

Media-relations@its.jnj.com
Investor contact:
Lauren Johnson
investor-relations@its.jnj.com


---

## Maurel &amp; Prom : Approbation de l’ANH pour l’acquisition d’une participation de 61% dans le permis gazier Sinu-9 en Colombie

**Date:** 2025-12-29
**Link:** [Maurel &amp; Prom : Approbation de l’ANH pour l’acquisition d’une participation de 61% dans le permis gazier Sinu-9 en Colombie](http://www.businesswire.com/news/home/20251228052007/fr/)

**Summary:** Etablissements Maurel & Prom S.A. (« M&P », le « Groupe ») (Paris:MAU) a le plaisir d’annoncer que l’Agence Nationale des Hydrocarbures colombienne (« ANH ») a délivré son approbation concernant les transactions précédemment annoncées relatives à l’acquisition par M&P d’une participation totale de 61% et du rôle d’opérateur dans la licence gazière Sinu-9 en Colombie. En conséquence, la condition d’obtention de l’approbation réglementaire de l’ANH est désormais satisfaite. Les parties vont procéder à la finalisation prochaine de l’opération, en remplissant les autres conditions usuelles de finalisation.

**Contact Information:**
Maurel & Prom
Relations actionnaires
Tél. : +33 (0)1 53 83 16 45
ir@maureletprom.fr
NewCap

NewCap
Relations investisseurs / médias
Tél. : +33 (0)1 44 71 98 53
maureletprom@newcap.eu


---

## Maurel &amp; Prom: ANH Approval for the Acquisition of a 61% Interest in the Sinu-9 Gas Permit in Colombia

**Date:** 2025-12-29
**Link:** [Maurel &amp; Prom: ANH Approval for the Acquisition of a 61% Interest in the Sinu-9 Gas Permit in Colombia](http://www.businesswire.com/news/home/20251228607589/en/Maurel-Prom-ANH-Approval-for-the-Acquisition-of-a-61-Interest-in-the-Sinu-9-Gas-Permit-in-Colombia/)

**Summary:** Etablissements Maurel & Prom S.A. (“M&P”, the “Group”) (Paris:MAU) is pleased to announce that Colombia’s National Hydrocarbons Agency (“ANH”) has released its approval in respect of the transactions previously announced relating to the acquisition by M&P of a total 61% working interest and operatorship in the Sinu-9 gas licence in Colombia. As a result, the regulatory approval condition relating to the ANH has now been satisfied. The parties will soon proceed towards closing, by completing the remaining customary closing conditions.

**Contact Information:**
Maurel & Prom
Shareholder relations
Tel.: +33 (0)1 53 83 16 45
ir@maureletprom.fr
NewCap

NewCap
Investor/media relations
Tel.: +33 (0)1 44 71 98 53
maureletprom@newcap.eu


---

